Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
| Cat. No. | Species | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|
| DR1-H52P6 | Human | Human DRD1 Full Length Protein (VLP) |
| Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
|---|---|---|---|---|---|---|---|---|---|---|
| Docarpamine | TA-870; TA-8704 | Approved | Tanadopa | Heart Failure | null | 1994-01-01 | Heart Failure | Details | ||
| Olanzapine/Fluoxetine hydrochloride | OFC | Approved | Eli Lilly And Company | Symbyax | United States | Bipolar Disorder | Eli Lilly And Company | 2003-12-24 | Depressive Disorder, Major; Bipolar Disorder; Depressive Disorder; Depressive Disorder, Treatment-Resistant | Details |
| Zuclopenthixol Hydrochloride | LU-0108 | Approved | Clopixol | Bipolar Disorder; Schizophrenia | null | 1962-01-01 | Schizophrenia; Bipolar Disorder | Details | ||
| Methylergometrine Maleate | Approved | Metenarin, Methergine, Ryegonivin, Basofortina, Methylergobrevin | Postpartum Hemorrhage; Uterine Cervical Incompetence; Uterine Hemorrhage; Uterine Inertia | Details | ||||||
| Samidorphan/Olanzapine | ALKS-3831 | Approved | Alkermes Plc | Lybalvi | United States | Bipolar Disorder; Schizophrenia | Alkermes Inc | 2021-05-28 | Schizophrenia; Bipolar Disorder; Psychotic Disorders; Bipolar and Related Disorders; Bipolar I Disorder; Alcoholism | Details |
| Olanzapine | ALKS-7921; LY-170052; LY-170053; INP-105 | Approved | Eli Lilly And Company | Lanzac, Midax, Zypadhera, Zalasta, Zyprexa, Zyprexa Velotab, Zyprexa Relprevv, Olansek, Zyprexa Zydis, Olanzapine ODF, 再普乐 | EU | Schizophrenia; Bipolar Disorder | null | 1996-09-27 | Emergence Delirium; Anorexia Nervosa; Fasting; Chemotherapy-induced nausea and vomiting; Cachexia; Borderline Personality Disorder; Bipolar II Disorder; Depressive Disorder, Treatment-Resistant; Nausea; Gambling; Vomiting; Autistic Disorder; Bipolar I Disorder; Feeding and Eating Disorders; Postoperative Nausea and Vomiting; Multiple Myeloma; Weight Loss; Malaria, Falciparum; Insulin Resistance; Bipolar Disorder; Anorexia; Opioid-Related Disorders; Neoplasms; Stomach Neoplasms; Depression; Esophageal Neoplasms; Depressive Disorder, Major; Schizophrenia; Biliary Tract Neoplasms; Solid tumours; Hematopoietic stem cell transplantation (HSCT); Substance-Related Disorders | Details |
| Phenylpropanolamine Hydrochloride | Approved | Nasadec, Nasathera, Pararhinol | Nasal Obstruction | Details | ||||||
| Olanzapine/Hydroxyzine pamoate | Approved | Nausea | Details | |||||||
| Stepholidine | Approved | Mainland China | Attention Deficit Disorder with Hyperactivity; Tourette Syndrome; Migraine Disorders; Headache | null | 1995-01-01 | Migraine Disorders; Headache; Attention Deficit Disorder with Hyperactivity; Tourette Syndrome | Details |
| Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
|---|---|---|---|---|---|
| Ecopipam | PSYRX-101; Sch-39166 | Phase 3 Clinical | Merck Sharp & Dohme Corp | Language Disorders; Speech Disorders; Self-Injurious Behavior; Lesch-Nyhan Syndrome; Childhood-Onset Fluency Disorder; Tourette Syndrome; Gambling; Stuttering | Details |
| Tavapadon | CVL-751; PF-6649751; PF-06649751 | Phase 3 Clinical | Pfizer Inc, Cerevel Therapeutics Llc | Renal Insufficiency; Parkinson Disease; Hepatic Insufficiency | Details |
| Thioridazine | TP-21 | Phase 3 Clinical | Novartis Pharma Ag | Schizophrenia; Anxiety Disorders; Carcinoma, Hepatocellular | Details |
| Olanzapine long acting injectable (Teva Pharmaceutical Industries) | TV-44749; TEV-‘749; mdc-TJK; TEV-749 | Phase 3 Clinical | Medincell SA | Schizophrenia | Details |
| Olanzapine/samidorphan (Qilu Pharmaceutical) | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Schizophrenia | Details | |
| PF-06412562 | PF-6412562; PF-06412562 | Phase 2 Clinical | Pfizer Inc | Schizophrenia; Schizophrenia Spectrum and Other Psychotic Disorders; Parkinson Disease | Details |
| Mevidalen | LY-3154207 | Phase 2 Clinical | Eli Lilly And Company | Alzheimer Disease; Parkinson Disease; Lewy Body Disease | Details |
| TGOF02N | TGOF-02N; TGOF02N; FKF02SC | Phase 2 Clinical | Fabre-Kramer | Schizophrenia | Details |
| Docarpamine (Martin Pharmaceuticals) | Phase 2 Clinical | Martin Pharmaceuticals Inc | Gastrointestinal Diseases; Liver Cirrhosis; Mouth Diseases | Details | |
| Razpipadon | CVL-871 | Phase 2 Clinical | Pfizer Inc | Dementia | Details |
| UCB-0022 | UCB-0022 | Phase 2 Clinical | Ucb Biopharma Srl | Parkinson Disease | Details |
| [11C]NNC-112 | [11C]NNC-112 | Phase 2 Clinical | Glaxosmithkline Plc | Diagnostic agents | Details |
| Lu-AF-28996 | Phase 1 Clinical | H. Lundbeck A/S | Parkinson Disease | Details | |
| asenapine schizophrenia (Livzon Pharmaceutical/LTS Lohmann Therapie-Systeme) | Phase 1 Clinical | Lts Lohmann Therapie-Systeme Ag | Schizophrenia | Details | |
| Olanzapine intranasal (Neurelis) | NRL-4; NRL-1004 | Phase 1 Clinical | Neurelis Inc | Bipolar Disorder | Details |
| Oxytocin/Methylergometrine Maleate | Phase 1 Clinical | Nanjing Gritpharma Co Ltd | Hemorrhage; Obstetric Labor Complications | Details | |
| ITI-333 | ITI-333 | Phase 1 Clinical | Intra-Cellular Therapies Inc | Pain; Mood Disorders; Opioid-Related Disorders | Details |
| PF-06730110 | PF-06730110; [18F]MNI-968 | Phase 1 Clinical | Invicro Llc | Nerve Degeneration | Details |
This web search service is supported by Google Inc.
A-Z
